Protagonist Therapeutics Inc (PTGX NASDAQ) stock market data APIs
$79.3753
1.22(1.5%)
as of November 7, 2025
Try our APIs with
free plan!
Protagonist Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Prev. Close
79.3753
Open
80.5935
High
81.3363
Low
77.4497
52 wk Range
33.31-93.2499
Market Cap
4 972 M
P/E Ratio
120.5151
Shares Outstanding
62 516 K
Revenue
209 M
EPS
-0.62
Beta
2.202
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Protagonist Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Protagonist Therapeutics Inc data using free add-ons & libraries
Get Protagonist Therapeutics Inc Fundamental Data
Protagonist Therapeutics Inc Fundamental data includes:
- Net Revenue: 209 M
- EBITDA: 24 868 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.6133
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Protagonist Therapeutics Inc News
New
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago. These f...
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting
Protagonist Therapeutics (PTGX) is preparing to present new clinical data on rusfertide at the 67th Annual ASH Meeting in December. The company will share Phase 3 results, safety updates, and long-ter...
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics, Inc. (BOLT) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consens...
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago. These f...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
